Target Name: ZNF169
NCBI ID: G169841
Other Name(s): Zinc finger protein 169 | zinc finger protein 169 | Zinc finger protein 169 (isoform 2) | ZNF169 variant 2 | Zinc finger protein 169, transcript variant 2 | ZN169_HUMAN

ZNF169: The Potential Drug Target and Biomarker for parkinson's disease

Parkinson's disease is a neurodegenerative disorder characterized by symptoms such as tremors, rigidity, bradykinesia, and postural instability. It affects millions of people worldwide, and the exact cause is not known, but research has identified several genetic and molecular mechanisms that contribute to its development. One of the genetic mutations that has been identified is the ZNF169 mutation, which has been shown to be associated with an increased risk of developing Parkinson's disease.

The ZNF169 gene is a member of the zinc finger gene family, which is known for its role in regulating gene expression and cell development. The ZNF169 gene is located on chromosome 12q and has been implicated in the development and progression of several neurological disorders, including Parkinson's disease.

Research has shown that individuals with the ZNF169 mutation have an increased risk of developing Parkinson's disease, and that the ZNF169 protein is involved in the development and progression of this disorder. Studies have also shown that reducing the level of ZNF169 in the brain can protect against the development of Parkinson's disease in animal models.

This raises the possibility that ZNF169 could be a drug target for the treatment of Parkinson's disease. By reducing the level of ZNF169 in the brain, it may be possible to slow down or even reverse the progression of Parkinson's disease. This could be an important step in the development of new treatments for this debilitating and often progressive disorder.

In addition to its potential as a drug target, ZNF169 has also been identified as a potential biomarker for Parkinson's disease. The ZNF169 protein has been shown to be expressed in the brains of individuals with Parkinson's disease, and levels of ZNF169 have been shown to be decreased in the brains of individuals with this disorder. This suggests that ZNF169 could be a useful biomarker for the diagnosis and assessment of Parkinson's disease.

The identification of ZNF169 as a potential drug target and biomarker for Parkinson's disease has important implications for the development of new treatments for this disorder. While further research is needed to fully understand the role of ZNF169 in the development and progression of Parkinson's disease, its potential as a drug target and biomarker is an encouraging sign that researchers may be on the path to developing new treatments for this debilitating disorder.

Protein Name: Zinc Finger Protein 169

Functions: May be involved in transcriptional regulation

More Common Targets

ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304